WO2024000060A1 - Salts of belumosudil, crystalline forms and pharmaceutical compositions thereof and their use in the treatment of chronic graft-versus-host disease - Google Patents
Salts of belumosudil, crystalline forms and pharmaceutical compositions thereof and their use in the treatment of chronic graft-versus-host disease Download PDFInfo
- Publication number
- WO2024000060A1 WO2024000060A1 PCT/CA2023/050852 CA2023050852W WO2024000060A1 WO 2024000060 A1 WO2024000060 A1 WO 2024000060A1 CA 2023050852 W CA2023050852 W CA 2023050852W WO 2024000060 A1 WO2024000060 A1 WO 2024000060A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- belumosudil
- salt
- peaks
- pxrd diffractogram
- expressed
- Prior art date
Links
- 229940074162 belumosudil Drugs 0.000 title claims abstract description 207
- GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide Chemical class CC(C)NC(=O)COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 GKHIVNAUVKXIIY-UHFFFAOYSA-N 0.000 title claims abstract description 142
- 150000003839 salts Chemical class 0.000 title claims abstract description 84
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 208000017760 chronic graft versus host disease Diseases 0.000 title claims abstract description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 20
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims abstract description 20
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 19
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 16
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 197
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 15
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 12
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 11
- 229960005164 acesulfame Drugs 0.000 claims description 8
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 7
- 150000002690 malonic acid derivatives Chemical class 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 5
- 229940116298 l- malic acid Drugs 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- -1 acesulfamate Chemical compound 0.000 abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 abstract description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 abstract description 3
- 239000007787 solid Substances 0.000 description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 239000000725 suspension Substances 0.000 description 24
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000012458 free base Substances 0.000 description 13
- 238000001914 filtration Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ILQJXEIRBCHLOM-UHFFFAOYSA-N CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5.CS(=O)(=O)O Chemical compound CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5.CS(=O)(=O)O ILQJXEIRBCHLOM-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940125466 rezurock Drugs 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PBWWPJDQYJXRII-UHFFFAOYSA-N 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide 3,3,3-trifluoropropanoic acid Chemical class OC(=O)CC(F)(F)F.CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1 PBWWPJDQYJXRII-UHFFFAOYSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 231100001127 band 4 compound Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- QXYCYSAGHGKNHM-UHFFFAOYSA-N dodecyl octadecanoate;magnesium Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCC QXYCYSAGHGKNHM-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- DSGUSEBCDAKBCM-UHFFFAOYSA-N ethane-1,2-disulfonic acid;dihydrate Chemical compound O.O.OS(=O)(=O)CCS(O)(=O)=O DSGUSEBCDAKBCM-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008016 pharmaceutical coating Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
- C07C309/08—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention is directed to novel salts of belumosudil and crystalline forms thereof, processes for the preparation thereof, pharmaceutical compositions containing these forms, and their use for the treatment of chronic graft-versus-host disease in a subject suffering therefrom.
- API active pharmaceutical ingredient
- Belumosudil trifluoroacetate salt is disclosed in WO 2006/105081 A2, which discloses a family of compounds that are stated to be useful as inhibitors of Rho kinase (ROCK).
- Further salts of belumosudil, including the methanesulfonate (mesylate), benzenesulfonate (besylate), and p-toluenesulfonate (tosylate) salts, and crystalline forms thereof, are reported in WO 2022/020850 A1 . i [0004] According to the review published by the U.S.
- solubility of individual salt and crystalline forms of a drug substance in an aqueous environment often correlates with their relative bioavailability, since the manner in which the salt or crystalline form dissolves can correspond to the amount of the drug substance that is available to be absorbed into the body to provide the intended therapeutic effect.
- One measure of solubility is intrinsic dissolution rate (IDR), which is defined as the dissolution rate of a substance under constant surface area conditions. For low solubility substances, higher IDR values can correlate with higher bioavailability following administration. Prediction of the solubility and IDR of a yet undiscovered salt and/or crystalline form of a substance is currently not possible.
- Different salt and/or crystalline forms of the same compound may have different crystal packing, thermodynamic, spectroscopic, kinetic, surface, and mechanical properties.
- different salt and/or crystalline forms may have different stability properties such that a particular crystalline form may be less sensitive to heat, relative humidity (RH), and/or light.
- RH relative humidity
- Different salts and/or crystalline forms of a compound may also be more susceptible to moisture uptake, resulting in a potential alteration of physical characteristics of the form such as flowability, density, or compressibility, which can lead to problems during formulation/tabletting and/or to changes in dissolution rate of the formulated drug product.
- a particular salt and/or crystalline form may provide more favourable compressibility and/or density properties, thereby providing more desirable characteristics for formulation and/or product manufacturing.
- Particular salts and/or crystalline forms may also have different solubilities, thereby providing different pharmacokinetic parameters, which allow for specific crystalline forms to be used in order to achieve specific pharmacokinetic targets. Differences in solubility between salts and/or crystalline forms are particularly relevant for compounds exhibiting low aqueous solubility, such as BCS Class IV drug substances, where even a modest increase in solubility can provide a beneficial enhancement in bioavailability.
- the present invention provides salts comprising belumosudil and a polycarboxylic acid selected from the group consisting of fumaric acid, maleic acid, L- malic acid, malonic acid, citric acid, and L-tartaric acid. Further provided by the present invention are salts comprising belumosudil and an acid having a sulfonyl group in the form of a sulfamate ester (acesulfame) or an organic sulfonic acid selected from the group consisting of 1 ,2-ethanedisulfonic acid and 2-hydroxyethanesulfonic acid.
- the polycarboxylic acids and sulfonic acids used in the present invention are pharmaceutically acceptable acids.
- Acesulfame in the form of acesulfamate potassium, is used as a sweetener in the food industry and as an inactive ingredient in drug products. Accordingly, it is expected that acesulfame can safely be used in materials intended for use in the preparation of pharmaceutical compositions intended for administration to humans.
- Embodiments of the belumosudil salts and crystalline forms of the present invention exhibit form stability at high temperature and high humidity.
- an L- malate salt of belumosudil In a preferred embodiment of the first aspect, the molar ratio of belumosudil to L-malic acid is approximately 1 :1. In a more preferred embodiment of the first aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 29 ( ⁇ 0.2°), at 6.4°, 7.6°, and 16.2°.
- the salt of the first aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °.
- the salt of the first aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 1.
- an acesulfamate salt of belumosudil In a preferred embodiment of the second aspect, the molar ratio of belumosudil to acesulfame is approximately 1 :1. In a more preferred embodiment of the second aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 4.8°, 6.5°, and 25.7°.
- the salt of the second aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°.
- the salt of the second aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 2.
- a fumarate salt of belumosudil In a preferred embodiment of the third aspect, the molar ratio of belumosudil to fumaric acid is approximately 1 :1. In a more preferred embodiment of the third aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 7.2°, 7.9°, and 21.1 °.
- the salt of the third aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 12.7°, 13.6°, 18.7°, 20.1 °, 21 .7°, and 23.8°.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 12.7°, 13.6°, 18.7°, 20.1 °, 21.7°, and 23.8°.
- the salt of the third aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 3.
- a maleate salt of belumosudil In a preferred embodiment of the fourth aspect, the molar ratio of belumosudil to maleic acid is approximately 1 :1. In a more preferred embodiment of the fourth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 5.3°, 6.9°, and 10.8°.
- the salt of the fourth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °.
- the salt of the fourth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 4.
- an isethionate salt of belumosudil In a preferred embodiment of the fifth aspect, the molar ratio of belumosudil to 2-hydroxyethanesulfonic acid is approximately 1 :1. In a more preferred embodiment of the fifth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 6.4°, 10.1 °, and 12.7°.
- the salt of the fifth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°.
- the salt of the fifth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 5.
- a malonate salt of belumosudil In a preferred embodiment of the sixth aspect, the molar ratio of belumosudil to malonic acid is approximately 1 :1.
- the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 6.3°, 9.8°, and 12.6°. More preferably, the salt of the sixth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°.
- the salt of the sixth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 6.
- an edisylate salt of belumosudil In a preferred embodiment of the seventh aspect, the molar ratio of belumosudil to 1 ,2-ethanedisulfonic acid is approximately 2:1. In a more preferred embodiment of the seventh aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 6.7°, 7.7°, and 9.7°.
- the salt of the seventh aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°.
- the salt of the seventh aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 7.
- a citrate salt of belumosudil In a preferred embodiment of the eighth aspect, the molar ratio of belumosudil to citric acid is approximately 1 :1. In a first more preferred embodiment of the eighth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 6.7°, 10.3°, and 11.7°.
- the salt of the eighth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°.
- the salt of the eighth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 8.
- the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 5.6°, 6.6°, and 17.7°. More preferably, the salt of the eighth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°.
- the salt of the eighth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 9.
- an L-tartrate salt of belumosudil In a preferred embodiment of the ninth aspect, the molar ratio of belumosudil to L-tartaric acid is approximately 1 :1. In a more preferred embodiment of the ninth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 ( ⁇ 0.2°), at 6.5°, 7.6°, and 16.3°.
- the salt of the ninth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of: 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°.
- the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°.
- the salt of the ninth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions ( ⁇ 0.2° 20) as those shown in Figure 10.
- a pharmaceutical composition comprising a salt of belumosudil according to the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth aspects of the invention, and one or more pharmaceutically acceptable excipients.
- the pharmaceutical composition is in the form of a solid oral dosage form.
- the pharmaceutical composition is a capsule or a tablet.
- the pharmaceutical composition of the tenth aspect comprises an amount of the belumosudil salt of the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth aspects that is equivalent to 200 mg of belumosudil free base.
- an eleventh aspect of the present invention there is provided the use of a salt of belumosudil according to the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth aspects of the invention, or the pharmaceutical compositions of the tenth aspect of the invention, in the treatment of chronic graft-versus-host disease.
- Figure 1 is a representative PXRD diffractogram of belumosudil L-malate Form APO-I as prepared in Example 1.
- Figure 2 is a representative PXRD diffractogram of belumosudil acesulfamate Form APO-I as prepared in Example 2.
- Figure 3 is a representative PXRD diffractogram of belumosudil fumarate Form APO-I as prepared in Example 3.
- Figure 4 is a representative PXRD diffractogram of belumosudil maleate Form APO-I as prepared in Example 4.
- Figure 5 is a representative PXRD diffractogram of belumosudil isethionate Form APO-I as prepared in Example 5.
- Figure 6 is a representative PXRD diffractogram of belumosudil malonate Form APO-I as prepared in Example 6.
- Figure 7 is a representative PXRD diffractogram of belumosudil edisylate Form APO-I as prepared in Example 7.
- Figure 8 is a representative PXRD diffractogram of belumosudil citrate Form APO-I as prepared in Example 8.
- Figure 9 is a representative PXRD diffractogram of belumosudil citrate Form APO-I I as prepared in Example 9.
- Figure 10 is a representative PXRD diffractogram of belumosudil L-tartrate Form APO-I as prepared in Example 10.
- the present invention provides novel salts of belumosudil and crystalline forms thereof providing improved properties over known salts of belumosudil.
- the belumosudil salts and crystalline forms of the present invention exhibit differences in properties when compared to known salts of belumosudil.
- properties that differ between the invention and known salts of belumosudil include crystal packing properties such as molar volume, density, and hygroscopicity; thermodynamic properties such as melting point and solubility; kinetic properties such as dissolution rate and chemical/polymorphic stability; surface properties such as crystal habit/particle morphology; and/or mechanical properties such as hardness, tensile strength, compactibility, tabletting, handling, flow, and blending.
- the improved properties provided by the salts and crystalline forms of the present invention provide practical advantages over known forms of belumosudil that can be exploited to meet specific needs in the manufacture and formulation of belumosudil.
- the intensity of a given peak observed in a PXRD diffractogram of a crystalline form may vary when compared to the same peak in the representative PXRD diffractograms provided in Figures 1 to 10.
- differences in relative peak intensities between peaks in a PXRD diffractogram for a given crystalline form may be observed when compared to the relative peak intensities of the peaks in the representative PXRD diffractograms of Figures 1 to 10. Any such differences may be due, in part, to the preferred orientation of the sample and its deviation from the ideal random sample orientation, the preparation of the sample for analysis, and the methodology applied for the analysis.
- Such variations are known and understood by a person of skill in the art, and any such variations do not depart from the invention disclosed herein.
- PXRD diffractograms of the crystalline forms of the present invention may, in some circumstances, display the same relative peak positions as observed in the representative PXRD diffractograms provided in Figures 1 to 10, with the exception that each peak is offset in the same direction, and by approximately the same amount, such that the overall PXRD diffractogram is substantially the same in appearance as the PXRD diffractograms of Figures 1 to 10, with the exception of the uniform offset in peak positions.
- the term ‘crystalline form’ refers to a substance, particularly a belumosudil salt, having a particular arrangement of its components in the crystal lattice, and which may be identified by physical characterization methods such as PXRD and/or DSC.
- room temperature refers to a temperature in the range of 20 °C to 25 °C.
- Belumosudil L-malate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 ( ⁇ 0.2°), at 6.4°, 7.6°, and 16.2°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 ( ⁇ 0.2°), selected from the group consisting of 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 ( ⁇ 0.2°), at 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °.
- PXRD studies of uncapped samples of belumosudil L-malate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
- FIG. 1 An illustrative PXRD diffractogram of belumosudil L-malate Form APO-I, as prepared in Example 1 , is shown in Figure 1.
- a peak listing comprising representative peaks from the PXRD diffractogram in Figure 1 , and their relative intensities, is provided in Table 1.
- the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
- Belumosudil acesulfamate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 ( ⁇ 0.2°), at 4.8°, 6.5°, and 25.7°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 ( ⁇ 0.2°), selected from the group consisting of 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 ( ⁇ 0.2°), at 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°.
- a new salt of belumosudil, belumosudil fumarate Form APO-I wherein the molar ratio of belumosudil to fumaric acid is approximately 1 :1.
- Belumosudil fumarate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 ( ⁇ 0.2°), at 7.2°, 7.9°, and 21.1 °.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 ( ⁇ 0.2°), selected from the group consisting of 12.7°, 13.6°, 18.7°, 20.1 °, 21.7°, and 23.8°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 12.7°, 13.6°, 18.7°, 20.1 °, 21.7°, and 23.8°.
- a new salt of belumosudil, belumosudil maleate Form APO-I wherein the molar ratio of belumosudil to maleic acid is approximately 1 :1 .
- Belumosudil maleate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 20 ( ⁇ 0.2°), at 5.3°, 6.9°, and 10.8°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °.
- FIG. 4 An illustrative PXRD diffractogram of belumosudil maleate Form APO-I, as prepared in Example 4, is shown in Figure 4.
- a peak listing comprising representative peaks from the PXRD diffractogram in Figure 4, and their relative intensities, is provided in Table 4.
- the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
- a new salt of belumosudil, belumosudil isethionate Form APO-I wherein the molar ratio of belumosudil to 2-hydroxyethanesulfonic acid is approximately 1 :1.
- Belumosudil isethionate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 20 ( ⁇ 0.2°), at 6.4°, 10.1 °, and 12.7°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 20 ( ⁇ 0.2°), selected from the group consisting of 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 20 ( ⁇ 0.2°), at 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°.
- PXRD studies of uncapped samples of belumosudil isethionate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
- FIG. 5 An illustrative PXRD diffractogram of belumosudil isethionate Form APO-I, as prepared in Example 5, is shown in Figure 5.
- a peak listing comprising representative peaks from the PXRD diffractogram in Figure 5, and their relative intensities, is provided in Table 5.
- the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
- a new salt of belumosudil, belumosudil malonate Form APO-I wherein the molar ratio of belumosudil to malonic acid is approximately 1 :1.
- Belumosudil malonate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 ( ⁇ 0.2°), at 6.3°, 9.8°, and 12.6°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 ( ⁇ 0.2°), selected from the group consisting of 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 ( ⁇ 0.2°), at 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°.
- PXRD studies of uncapped samples of belumosudil malonate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
- FIG. 6 An illustrative PXRD diffractogram of belumosudil malonate Form APO-I, as prepared in Example 6, is shown in Figure 6.
- a peak listing comprising representative peaks from the PXRD diffractogram in Figure 6, and their relative intensities, is provided in Table 6.
- the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
- Belumosudil edisylate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 ( ⁇ 0.2°), at 6.7°, 7.7°, and 9.7°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 ( ⁇ 0.2°), selected from the group consisting of 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 ( ⁇ 0.2°), at 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°.
- PXRD studies of uncapped samples of belumosudil edisylate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
- FIG. 7 An illustrative PXRD diffractogram of belumosudil edisylate Form APO-I, as prepared in Example 7, is shown in Figure 7.
- the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
- Belumosudil citrate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 ( ⁇ 0.2°), at 6.7°, 10.3°, and 11.7°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 ( ⁇ 0.2°), selected from the group consisting of 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 29 ( ⁇ 0.2°), at 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°.
- PXRD studies of uncapped samples of belumosudil citrate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
- FIG. 8 An illustrative PXRD diffractogram of belumosudil citrate Form APO-I, as prepared in Example 8, is shown in Figure 8.
- a peak listing comprising representative peaks from the PXRD in Figure 8, and their relative intensities, is provided in Table 8.
- the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
- a new salt of belumosudil, belumosudil citrate Form APO-II wherein the molar ratio of belumosudil to citric acid is approximately 1 :1.
- Belumosudil citrate Form APO-II can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 ( ⁇ 0.2°), at 5.6°, 6.6°, and 17.7°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 ( ⁇ 0.2°), selected from the group consisting of 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 ( ⁇ 0.2°), at 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°.
- FIG. 9 An illustrative PXRD diffractogram of belumosudil citrate Form APO-II, as prepared in Example 9, is shown in Figure 9.
- Table 9 An illustrative of the PXRD diffractogram that is provided for the belumosudil citrate Form APO-II of the present invention, the relative intensities of the peaks are variable.
- the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
- Belumosudil L-tartrate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 ( ⁇ 0.2°), at 6.5°, 7.6°, and 16.3°.
- the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 ( ⁇ 0.2°), selected from the group consisting of 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 ( ⁇ 0.2°), at 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°.
- FIG. 10 An illustrative PXRD diffractogram of belumosudil L-tartrate Form APO-I, as prepared in Example 10, is shown in Figure 10.
- a peak listing comprising representative peaks from the PXRD in Figure 10, and their relative intensities, is provided in Table 10.
- the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
- a pharmaceutical composition comprising one or more belumosudil salt(s) selected from the group consisting of belumosudil L-malate, belumosudil acesulfamate, belumosudil fumarate, belumosudil maleate, belumosudil isethionate, belumosudil malonate, belumosudil edisylate, belumosudil citrate, belumosudil L-tartrate, and combinations thereof, with one or more pharmaceutically acceptable excipients.
- belumosudil salt(s) selected from the group consisting of belumosudil L-malate, belumosudil acesulfamate, belumosudil fumarate, belumosudil maleate, belumosudil isethionate, belumosudil malonate, belumosudil edisylate, belumosudil citrate, belumosudi
- the pharmaceutical composition comprises one or more crystalline form(s) of a belumosudil salt selected from the group consisting of belumosudil L-malate Form APO-I, belumosudil acesulfamate Form APO-I, belumosudil fumarate Form APO-I, belumosudil maleate Form APO-I, belumosudil isethionate Form APO-I, belumosudil malonate Form APO-I, belumosudil edisylate Form APO-I, belumosudil citrate Form APO-I, belumosudil citrate Form APO-II, belumosudil L-tartrate Form APO-I, and combinations thereof, with one or more pharmaceutically acceptable excipients.
- a belumosudil salt selected from the group consisting of belumosudil L-malate Form APO-I, belumosudil acesulfamate Form
- the pharmaceutical composition is a solid dosage form suitable for oral administration, such as a capsule, tablet, pill, powder or granulate. Most preferably, the pharmaceutical composition is a tablet.
- the pharmaceutical composition provides a dose of one or more belumosudil salt(s) selected from the group consisting of belumosudil L-malate, belumosudil acesulfamate, belumosudil fumarate, belumosudil maleate, belumosudil isethionate, belumosudil malonate, belumosudil edisylate, belumosudil citrate, belumosudil L-tartrate, such that the total is equivalent to the 200 mg of belumosudil free base found in REZUROCK® drug products.
- belumosudil salt(s) selected from the group consisting of belumosudil L-malate, belumosudil acesulfamate, belumosudil fuma
- Suitable pharmaceutically acceptable excipients are preferably inert with respect to the belumosudil salts of the present invention, and may include, for example, one or more excipients selected from binders such as lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, copovidone, gelatine, polyvinylpyrrolidone (PVP), and sodium alginate; fillers or diluents such as lactose, sugar, starches, modified starches, mannitol, sorbitol, inorganic salts, cellulose derivatives (e.g., microcrystalline cellulose, cellulose), calcium sulphate, xylitol, and lactitol; disintegrants such as
- excipients including preservatives, stabilisers, anti-oxidants, silica flow conditioners, antiadherents, or glidants may be added as required.
- suitable excipients and the preparation of solid oral dosage forms are well known to person of skill in the art, and is described generally, for example, in Remington The Science and Practice of Pharmacy 21 st Edition (Lippincott Williams & Wilkins: Philadelphia; 2006; Chapter 45).
- the solid dosage forms may be prepared with coatings, such as enteric coatings and extended-release coatings, using standard pharmaceutical coatings.
- coatings such as enteric coatings and extended-release coatings, using standard pharmaceutical coatings.
- Such coatings, and their application, are well known to persons skilled in the art, and are described, for example, in Remington The Science and Practice of Pharmacy 21 st Edition (Lippincott Williams & Wilkins: Philadelphia; 2006; Chapter 46).
- the belumosudil free base used as a starting material in the following examples was commercially available and in the form of N1 as described in WO 2021/129589 A1.
- Acesulfame used as starting material in the following examples was obtained by stirring an ethyl acetate suspension of acesulfame potassium and a stoichiometric amount of 85 % phosphoric acid for about 3 hours, filtering the organic layer and concentrating the solution to dryness.
Abstract
The present invention provides novel salts of belumosudil (I) and crystalline forms thereof. Specific salts of belumosudil provided by the present invention include L-malate, acesulfamate, fumarate, maleate, isethionate, malonate, edisylate, citrate, and L-tartrate. Also provided are pharmaceutical compositions comprising the belumosudil salts and crystalline forms thereof and the use of these salts in the treatment of chronic graft- versus-host disease in a subject suffering therefrom.
Description
SALTS OF BELUMOSUDIL, CRYSTALLINE FORMS AND PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
TECHNICAL FIELD
[0001] The present invention is directed to novel salts of belumosudil and crystalline forms thereof, processes for the preparation thereof, pharmaceutical compositions containing these forms, and their use for the treatment of chronic graft-versus-host disease in a subject suffering therefrom.
BACKGROUND
[0002] Belumosudil (1 ), or 2-{3-[4-(1/-/-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-/\/- (propan-2-yl)acetamide, in the form of its methanesulfonate (mesylate) salt (1 :1), is the active pharmaceutical ingredient (API) in branded pharmaceutical REZUROCK®, a drug indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
[0003] Belumosudil trifluoroacetate salt is disclosed in WO 2006/105081 A2, which discloses a family of compounds that are stated to be useful as inhibitors of Rho kinase (ROCK). Further salts of belumosudil, including the methanesulfonate (mesylate), benzenesulfonate (besylate), and p-toluenesulfonate (tosylate) salts, and crystalline forms thereof, are reported in WO 2022/020850 A1 . i
[0004] According to the review published by the U.S. Center for Drug Evaluation and Research (CDER) in connection with the approval of REZUROCK® (NDA 214783), the drug substance belumosudil mesylate has low solubility and low permeability, placing it in Class IV of the Biopharmaceutics Classification System (BCS). Of the four BCS Classes, Class IV drug substances present the most challenges to achieving adequate bioavailability.
[0005] The solubility of individual salt and crystalline forms of a drug substance in an aqueous environment often correlates with their relative bioavailability, since the manner in which the salt or crystalline form dissolves can correspond to the amount of the drug substance that is available to be absorbed into the body to provide the intended therapeutic effect. One measure of solubility is intrinsic dissolution rate (IDR), which is defined as the dissolution rate of a substance under constant surface area conditions. For low solubility substances, higher IDR values can correlate with higher bioavailability following administration. Prediction of the solubility and IDR of a yet undiscovered salt and/or crystalline form of a substance is currently not possible.
[0006] Different salt and/or crystalline forms of the same compound may have different crystal packing, thermodynamic, spectroscopic, kinetic, surface, and mechanical properties. For example, different salt and/or crystalline forms may have different stability properties such that a particular crystalline form may be less sensitive to heat, relative humidity (RH), and/or light. Different salts and/or crystalline forms of a compound may also be more susceptible to moisture uptake, resulting in a potential alteration of physical characteristics of the form such as flowability, density, or compressibility, which can lead to problems during formulation/tabletting and/or to changes in dissolution rate of the formulated drug product. For example, unintended absorption of moisture by a hygroscopic salt and/or crystalline form of a drug substance can alter its compressibility during tabletting, resulting in a softer tablet having a faster dissolution rate following administration. A particular salt and/or crystalline form may provide more favourable compressibility and/or density properties, thereby providing more desirable characteristics for formulation and/or product manufacturing. Particular salts and/or crystalline forms may also have different solubilities, thereby providing different
pharmacokinetic parameters, which allow for specific crystalline forms to be used in order to achieve specific pharmacokinetic targets. Differences in solubility between salts and/or crystalline forms are particularly relevant for compounds exhibiting low aqueous solubility, such as BCS Class IV drug substances, where even a modest increase in solubility can provide a beneficial enhancement in bioavailability.
[0007] There exists a need for novel salts and crystalline forms of belumosudil having improved properties for use in providing drug products containing belumosudil, and commercially amenable processes for their manufacture.
SUMMARY OF THE INVENTION
[0008] The present invention provides salts comprising belumosudil and a polycarboxylic acid selected from the group consisting of fumaric acid, maleic acid, L- malic acid, malonic acid, citric acid, and L-tartaric acid. Further provided by the present invention are salts comprising belumosudil and an acid having a sulfonyl group in the form of a sulfamate ester (acesulfame) or an organic sulfonic acid selected from the group consisting of 1 ,2-ethanedisulfonic acid and 2-hydroxyethanesulfonic acid. The polycarboxylic acids and sulfonic acids used in the present invention are pharmaceutically acceptable acids. Acesulfame, in the form of acesulfamate potassium, is used as a sweetener in the food industry and as an inactive ingredient in drug products. Accordingly, it is expected that acesulfame can safely be used in materials intended for use in the preparation of pharmaceutical compositions intended for administration to humans.
[0009] Embodiments of the belumosudil salts and crystalline forms of the present invention exhibit form stability at high temperature and high humidity.
[0010] Accordingly, in a first aspect of the present invention, there is provided an L- malate salt of belumosudil. In a preferred embodiment of the first aspect, the molar ratio of belumosudil to L-malic acid is approximately 1 :1. In a more preferred embodiment of the first aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 29 (± 0.2°), at 6.4°, 7.6°, and 16.2°. More preferably, the salt of the
first aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °. In a further preferred embodiment of the first aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °. Preferably, the salt of the first aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 1.
[0011 ] In a second aspect of the present invention, there is provided an acesulfamate salt of belumosudil. In a preferred embodiment of the second aspect, the molar ratio of belumosudil to acesulfame is approximately 1 :1. In a more preferred embodiment of the second aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 4.8°, 6.5°, and 25.7°. More preferably, the salt of the second aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°. In a further preferred embodiment of the second aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°. Preferably, the salt of the second aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 2.
[0012] In a third aspect of the present invention, there is provided a fumarate salt of belumosudil. In a preferred embodiment of the third aspect, the molar ratio of belumosudil to fumaric acid is approximately 1 :1. In a more preferred embodiment of the third aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 7.2°, 7.9°, and 21.1 °. More preferably, the salt of the third aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 12.7°, 13.6°, 18.7°, 20.1 °, 21 .7°, and 23.8°. In a further preferred embodiment of the third aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 12.7°, 13.6°, 18.7°, 20.1 °, 21.7°, and 23.8°. Preferably, the salt of the third aspect of the
invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 3.
[0013] In a fourth aspect of the present invention, there is provided a maleate salt of belumosudil. In a preferred embodiment of the fourth aspect, the molar ratio of belumosudil to maleic acid is approximately 1 :1. In a more preferred embodiment of the fourth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 5.3°, 6.9°, and 10.8°. More preferably, the salt of the fourth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °. In a further preferred embodiment of the fourth aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °. Preferably, the salt of the fourth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 4.
[0014] In a fifth aspect of the present invention, there is provided an isethionate salt of belumosudil. In a preferred embodiment of the fifth aspect, the molar ratio of belumosudil to 2-hydroxyethanesulfonic acid is approximately 1 :1. In a more preferred embodiment of the fifth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.4°, 10.1 °, and 12.7°. More preferably, the salt of the fifth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°. In a further preferred embodiment of the fifth aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°. Preferably, the salt of the fifth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 5.
[0015] In a sixth aspect of the present invention, there is provided a malonate salt of belumosudil. In a preferred embodiment of the sixth aspect, the molar ratio of belumosudil to malonic acid is approximately 1 :1. In a more preferred embodiment of the sixth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in
degrees 20 (± 0.2°), at 6.3°, 9.8°, and 12.6°. More preferably, the salt of the sixth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°. In a further preferred embodiment of the sixth aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°. Preferably, the salt of the sixth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 6.
[0016] In a seventh aspect of the present invention, there is provided an edisylate salt of belumosudil. In a preferred embodiment of the seventh aspect, the molar ratio of belumosudil to 1 ,2-ethanedisulfonic acid is approximately 2:1. In a more preferred embodiment of the seventh aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.7°, 7.7°, and 9.7°. More preferably, the salt of the seventh aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°. In a further preferred embodiment of the seventh aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°. Preferably, the salt of the seventh aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 7.
[0017] In an eighth aspect of the present invention, there is provided a citrate salt of belumosudil. In a preferred embodiment of the eighth aspect, the molar ratio of belumosudil to citric acid is approximately 1 :1. In a first more preferred embodiment of the eighth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.7°, 10.3°, and 11.7°. More preferably, the salt of the eighth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°. In a further preferred embodiment of the eighth aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°. Preferably, the salt of the eighth
aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 8. In a second more preferred embodiment of the eighth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 5.6°, 6.6°, and 17.7°. More preferably, the salt of the eighth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°. In a further preferred embodiment of the eighth aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°. Preferably, the salt of the eighth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 9.
[0018] In a ninth aspect of the present invention, there is provided an L-tartrate salt of belumosudil. In a preferred embodiment of the ninth aspect, the molar ratio of belumosudil to L-tartaric acid is approximately 1 :1. In a more preferred embodiment of the ninth aspect, the salt is characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.5°, 7.6°, and 16.3°. More preferably, the salt of the ninth aspect is characterized by a PXRD diffractogram further comprising at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°. In a further preferred embodiment of the ninth aspect, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°. Preferably, the salt of the ninth aspect of the invention provides a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 10.
[0019] In a tenth aspect of the present invention, there is provided a pharmaceutical composition comprising a salt of belumosudil according to the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth aspects of the invention, and one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical composition is in the form of a solid oral dosage form. Most preferably, the pharmaceutical composition is a capsule or a tablet. Preferably, the pharmaceutical composition of the tenth aspect
comprises an amount of the belumosudil salt of the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth aspects that is equivalent to 200 mg of belumosudil free base.
[0020] In an eleventh aspect of the present invention, there is provided the use of a salt of belumosudil according to the first, second, third, fourth, fifth, sixth, seventh, eighth, or ninth aspects of the invention, or the pharmaceutical compositions of the tenth aspect of the invention, in the treatment of chronic graft-versus-host disease.
[0021 ] Other aspects and features of the present invention will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Embodiments of the present invention are described, by way of example only, with reference to the attached Figures.
[0023] Figure 1 is a representative PXRD diffractogram of belumosudil L-malate Form APO-I as prepared in Example 1.
[0024] Figure 2 is a representative PXRD diffractogram of belumosudil acesulfamate Form APO-I as prepared in Example 2.
[0025] Figure 3 is a representative PXRD diffractogram of belumosudil fumarate Form APO-I as prepared in Example 3.
[0026] Figure 4 is a representative PXRD diffractogram of belumosudil maleate Form APO-I as prepared in Example 4.
[0027] Figure 5 is a representative PXRD diffractogram of belumosudil isethionate Form APO-I as prepared in Example 5.
[0028] Figure 6 is a representative PXRD diffractogram of belumosudil malonate Form APO-I as prepared in Example 6.
[0029] Figure 7 is a representative PXRD diffractogram of belumosudil edisylate Form APO-I as prepared in Example 7.
[0030] Figure 8 is a representative PXRD diffractogram of belumosudil citrate Form APO-I as prepared in Example 8.
[0031] Figure 9 is a representative PXRD diffractogram of belumosudil citrate Form APO-I I as prepared in Example 9.
[0032] Figure 10 is a representative PXRD diffractogram of belumosudil L-tartrate Form APO-I as prepared in Example 10.
DETAILED DESCRIPTION
[0033] The present invention provides novel salts of belumosudil and crystalline forms thereof providing improved properties over known salts of belumosudil.
[0034] The belumosudil salts and crystalline forms of the present invention exhibit differences in properties when compared to known salts of belumosudil. Depending on the specific salts and crystalline forms of the invention used, properties that differ between the invention and known salts of belumosudil include crystal packing properties such as molar volume, density, and hygroscopicity; thermodynamic properties such as melting point and solubility; kinetic properties such as dissolution rate and chemical/polymorphic stability; surface properties such as crystal habit/particle morphology; and/or mechanical properties such as hardness, tensile strength, compactibility, tabletting, handling, flow, and blending. The improved properties provided by the salts and crystalline forms of the present invention provide practical advantages over known forms of belumosudil that can be exploited to meet specific needs in the manufacture and formulation of belumosudil.
[0035] Depending on the manner in which the crystalline forms of the present invention are prepared, and the methodology and instrument used for PXRD analysis, the intensity of a given peak observed in a PXRD diffractogram of a crystalline form may vary when compared to the same peak in the representative PXRD diffractograms provided in Figures 1 to 10. Thus, differences in relative peak intensities between peaks in a PXRD diffractogram for a given crystalline form may be observed when compared to the relative peak intensities of the peaks in the representative PXRD diffractograms of Figures 1 to 10. Any such differences may be due, in part, to the preferred orientation of the sample
and its deviation from the ideal random sample orientation, the preparation of the sample for analysis, and the methodology applied for the analysis. Such variations are known and understood by a person of skill in the art, and any such variations do not depart from the invention disclosed herein.
[0036] In addition to the differences in relative peak intensities that may be observed in comparison to the representative PXRD diffractograms provided in Figures 1 to 10, it is understood that individual peak positions may vary between ±0.2° 29 from the values observed in the representative PXRD diffractograms provided in Figures 1 to 10 for the crystalline form of the invention, or listed in Tables 1 to 10. Such variations are known and understood by a person of skill in the art, and any such variations do not depart from the invention disclosed herein.
[0037] Further, depending on the instrument used for X-ray analysis and its calibration, uniform offsets in the peak position of each peak in a PXRD diffractogram of greater that 0.2° 26 may be observed when compared to the representative PXRD diffractograms provided in Figures 1 to 10. Thus, PXRD diffractograms of the crystalline forms of the present invention may, in some circumstances, display the same relative peak positions as observed in the representative PXRD diffractograms provided in Figures 1 to 10, with the exception that each peak is offset in the same direction, and by approximately the same amount, such that the overall PXRD diffractogram is substantially the same in appearance as the PXRD diffractograms of Figures 1 to 10, with the exception of the uniform offset in peak positions. The observation of any such uniform peak shift in a PXRD diffractogram does not depart from the invention disclosed herein given that the relative peak positions of the individual peaks within the PXRD diffractogram remain consistent with the relative peak positions observed in the PXRD diffractograms of Figures 1 to 10.
[0038] As used herein, the term ‘crystalline form’ refers to a substance, particularly a belumosudil salt, having a particular arrangement of its components in the crystal lattice, and which may be identified by physical characterization methods such as PXRD and/or DSC.
[0039] As used herein, the term “room temperature” refers to a temperature in the range of 20 °C to 25 °C.
[0040] When describing the embodiments of the present invention there may be a common variance to a given temperature or time that would be understood or expected by the person skilled in the art to provide substantially the same result. For example, when reference is made to a particular temperature, it is to be understood by the person skilled in the art that there is an allowable variance of ±5 °C associated with that temperature. When reference is made to a particular time, it is to be understood that there is an allowable variance of ±10 minutes when the time is one or two hours, and ±1 hour when longer periods of time are referenced.
[0041 ] In a first embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil L-malate Form APO-I, wherein the molar ratio of belumosudil to L-malic acid is approximately 1 :1.
[0042] Belumosudil L-malate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 (± 0.2°), at 6.4°, 7.6°, and 16.2°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 (± 0.2°), selected from the group consisting of 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 (± 0.2°), at 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °. PXRD studies of uncapped samples of belumosudil L-malate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
[0043] An illustrative PXRD diffractogram of belumosudil L-malate Form APO-I, as prepared in Example 1 , is shown in Figure 1. A peak listing, comprising representative peaks from the PXRD diffractogram in Figure 1 , and their relative intensities, is provided in Table 1. Although illustrative of the PXRD diffractogram that is provided for the belumosudil L-malate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative
intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0044] In a second embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil acesulfamate Form APO-I, wherein the molar ratio of belumosudil to acesulfame is approximately 1 :1.
[0045] Belumosudil acesulfamate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 (± 0.2°), at 4.8°, 6.5°, and 25.7°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 (± 0.2°), selected from the group consisting of 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 (± 0.2°), at 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°. PXRD studies of uncapped samples of belumosudil acesulfamate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
[0046] An illustrative PXRD diffractogram of belumosudil acesulfamate Form APO-I, as prepared in Example 2, is shown in Figure 2. A peak listing, comprising representative peaks from the PXRD diffractogram in Figure 2, and their relative intensities, is provided in Table 2. Although illustrative of the PXRD diffractogram that is provided for the belumosudil acesulfamate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0047] In a third embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil fumarate Form APO-I, wherein the molar ratio of belumosudil to fumaric acid is approximately 1 :1.
[0048] Belumosudil fumarate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 (± 0.2°), at 7.2°, 7.9°, and 21.1 °. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 (± 0.2°), selected from the group consisting of 12.7°, 13.6°, 18.7°, 20.1 °, 21.7°, and 23.8°. More preferably, the PXRD diffractogram
further comprises peaks, expressed in degrees 20 (± 0.2°), at 12.7°, 13.6°, 18.7°, 20.1 °, 21.7°, and 23.8°. PXRD studies of uncapped samples of belumosudil fumarate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred. [0049] An illustrative PXRD diffractogram of belumosudil fumarate Form APO-I, as prepared in Example 3, is shown in Figure 3. A peak listing, comprising representative peaks from the PXRD diffractogram in Figure 3, and their relative intensities, is provided in Table 3. Although illustrative of the PXRD diffractogram that is provided for the belumosudil fumarate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0050] In a fourth embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil maleate Form APO-I, wherein the molar ratio of belumosudil to maleic acid is approximately 1 :1 .
[0051 ] Belumosudil maleate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees
20 (± 0.2°), at 5.3°, 6.9°, and 10.8°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °. PXRD studies of uncapped samples of belumosudil maleate Form APO-
I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
[0052] An illustrative PXRD diffractogram of belumosudil maleate Form APO-I, as prepared in Example 4, is shown in Figure 4. A peak listing, comprising representative peaks from the PXRD diffractogram in Figure 4, and their relative intensities, is provided in Table 4. Although illustrative of the PXRD diffractogram that is provided for the belumosudil maleate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0053] In a fifth embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil isethionate Form APO-I, wherein the molar ratio of belumosudil to 2-hydroxyethanesulfonic acid is approximately 1 :1.
[0054] Belumosudil isethionate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 20 (± 0.2°), at 6.4°, 10.1 °, and 12.7°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 20 (± 0.2°), selected from the group consisting of 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 20 (± 0.2°), at 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°. PXRD studies of uncapped samples of belumosudil isethionate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred. [0055] An illustrative PXRD diffractogram of belumosudil isethionate Form APO-I, as prepared in Example 5, is shown in Figure 5. A peak listing, comprising representative peaks from the PXRD diffractogram in Figure 5, and their relative intensities, is provided in Table 5. Although illustrative of the PXRD diffractogram that is provided for the belumosudil isethionate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0056] In a sixth embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil malonate Form APO-I, wherein the molar ratio of belumosudil to malonic acid is approximately 1 :1.
[0057] Belumosudil malonate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 (± 0.2°), at 6.3°, 9.8°, and 12.6°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 (± 0.2°), selected from the group consisting of 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 (± 0.2°), at 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°. PXRD studies of uncapped samples of belumosudil malonate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
[0058] An illustrative PXRD diffractogram of belumosudil malonate Form APO-I, as prepared in Example 6, is shown in Figure 6. A peak listing, comprising representative peaks from the PXRD diffractogram in Figure 6, and their relative intensities, is provided in Table 6. Although illustrative of the PXRD diffractogram that is provided for the belumosudil malonate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0059] In a seventh embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil edisylate Form APO-I, wherein the molar ratio of belumosudil to 1 ,2-ethanedisulfonic acid is approximately 2:1.
[0060] Belumosudil edisylate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 (± 0.2°), at 6.7°, 7.7°, and 9.7°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 (± 0.2°), selected from the group consisting of 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 (± 0.2°), at 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°. PXRD studies of uncapped samples of belumosudil edisylate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
[0061 ] An illustrative PXRD diffractogram of belumosudil edisylate Form APO-I, as prepared in Example 7, is shown in Figure 7. A peak listing, comprising representative peaks from the PXRD diffractogram in Figure 7, and their relative intensities, is provided in Table 7. Although illustrative of the PXRD diffractogram that is provided for the belumosudil edisylate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0062] In an eighth embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil citrate Form APO-I, wherein the molar ratio of belumosudil to citric acid is approximately 1 :1.
[0063] Belumosudil citrate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 (± 0.2°), at 6.7°, 10.3°, and 11.7°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 (± 0.2°), selected from the group consisting of 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 29 (± 0.2°), at 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°. PXRD studies of uncapped samples of belumosudil citrate Form APO-I maintained in a 40 °C/75% RH stability chamber for at least 4 weeks showed that no change in the crystalline form occurred.
[0064] An illustrative PXRD diffractogram of belumosudil citrate Form APO-I, as prepared in Example 8, is shown in Figure 8. A peak listing, comprising representative peaks from the PXRD in Figure 8, and their relative intensities, is provided in Table 8. Although illustrative of the PXRD diffractogram that is provided for the belumosudil citrate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0065] In a ninth embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil citrate Form APO-II, wherein the molar ratio of belumosudil to citric acid is approximately 1 :1.
[0066] Belumosudil citrate Form APO-II can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 (± 0.2°), at 5.6°, 6.6°, and 17.7°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 (± 0.2°), selected from the group consisting of 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 (± 0.2°), at 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°.
[0067] An illustrative PXRD diffractogram of belumosudil citrate Form APO-II, as prepared in Example 9, is shown in Figure 9. A peak listing, comprising representative peaks from the PXRD in Figure 9, and their relative intensities, is provided in Table 9. Although illustrative of the PXRD diffractogram that is provided for the belumosudil citrate Form APO-II of the present invention, the relative intensities of the peaks are variable.
Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0068] In a tenth embodiment of the present invention, there is provided a new salt of belumosudil, belumosudil L-tartrate Form APO-I, wherein the molar ratio of belumosudil to L-tartaric acid is approximately 1 :1.
[0069] Belumosudil L-tartrate Form APO-I can be characterized by a PXRD diffractogram comprising, among other peaks, characteristic peaks, expressed in degrees 29 (± 0.2°), at 6.5°, 7.6°, and 16.3°. Preferably, the PXRD diffractogram further comprises at least three peaks, expressed in degrees 26 (± 0.2°), selected from the group consisting of 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°. More preferably, the PXRD diffractogram further comprises peaks, expressed in degrees 26 (± 0.2°), at 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°.
[0070] An illustrative PXRD diffractogram of belumosudil L-tartrate Form APO-I, as prepared in Example 10, is shown in Figure 10. A peak listing, comprising representative peaks from the PXRD in Figure 10, and their relative intensities, is provided in Table 10. Although illustrative of the PXRD diffractogram that is provided for the belumosudil L-
tartrate Form APO-I of the present invention, the relative intensities of the peaks are variable. Thus, depending on a particular sample, the prominence or relative intensity of the peaks observed may differ from those in the illustrative PXRD diffractogram and peak listing.
[0071 ] In an eleventh embodiment of the invention, there is provided a pharmaceutical composition comprising one or more belumosudil salt(s) selected from the group consisting of belumosudil L-malate, belumosudil acesulfamate, belumosudil fumarate, belumosudil maleate, belumosudil isethionate, belumosudil malonate, belumosudil edisylate, belumosudil citrate, belumosudil L-tartrate, and combinations thereof, with one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical composition comprises one or more crystalline form(s) of a belumosudil salt selected from the group consisting of belumosudil L-malate Form APO-I, belumosudil acesulfamate Form APO-I, belumosudil fumarate Form APO-I, belumosudil maleate Form APO-I, belumosudil isethionate Form APO-I, belumosudil malonate Form APO-I, belumosudil edisylate Form APO-I, belumosudil citrate Form APO-I, belumosudil citrate Form APO-II,
belumosudil L-tartrate Form APO-I, and combinations thereof, with one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical composition is a solid dosage form suitable for oral administration, such as a capsule, tablet, pill, powder or granulate. Most preferably, the pharmaceutical composition is a tablet. Preferably, the pharmaceutical composition provides a dose of one or more belumosudil salt(s) selected from the group consisting of belumosudil L-malate, belumosudil acesulfamate, belumosudil fumarate, belumosudil maleate, belumosudil isethionate, belumosudil malonate, belumosudil edisylate, belumosudil citrate, belumosudil L-tartrate, such that the total is equivalent to the 200 mg of belumosudil free base found in REZUROCK® drug products.
[0072] Suitable pharmaceutically acceptable excipients are preferably inert with respect to the belumosudil salts of the present invention, and may include, for example, one or more excipients selected from binders such as lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, copovidone, gelatine, polyvinylpyrrolidone (PVP), and sodium alginate; fillers or diluents such as lactose, sugar, starches, modified starches, mannitol, sorbitol, inorganic salts, cellulose derivatives (e.g., microcrystalline cellulose, cellulose), calcium sulphate, xylitol, and lactitol; disintegrants such as croscarmellose sodium, crospovidone, polyvinylpyrrolidone, sodium starch glycollate, com starch, microcrystalline cellulose, hydroxypropyl methylcellulose, and hydroxypropyl cellulose; lubricants such as magnesium stearate, magnesium lauryl stearate, sodium stearyl fumarate, stearic acid, calcium stearate, zinc stearate, potassium benzoate, sodium benzoate, myristic acid, palmitic acid, mineral oil, hydrogenated castor oil, medium-chain triglycerides, poloxamer, polyethylene glycol, and talc; and dispersants or solubility enhancing agents, such cyclodextrins, glyceryl monostearate, hypromellose, meglumine, poloxamer, polyoxyethylene castor oil derivatives, polyoxyethylene stearates, polyoxylglycerides, povidone, and stearic acid. Other excipients including preservatives, stabilisers, anti-oxidants, silica flow conditioners, antiadherents, or glidants may be added as required. Other suitable excipients and the preparation of solid oral dosage forms are well known to person of skill in the art, and is described generally, for
example, in Remington The Science and Practice of Pharmacy 21st Edition (Lippincott Williams & Wilkins: Philadelphia; 2006; Chapter 45).
[0073] Optionally, when the pharmaceutical compositions are solid dosage forms, the solid dosage forms may be prepared with coatings, such as enteric coatings and extended-release coatings, using standard pharmaceutical coatings. Such coatings, and their application, are well known to persons skilled in the art, and are described, for example, in Remington The Science and Practice of Pharmacy 21st Edition (Lippincott Williams & Wilkins: Philadelphia; 2006; Chapter 46).
EXAMPLES
[0074] The following non-limiting examples are illustrative of some of the aspects and embodiments of the invention described herein.
[0075] The belumosudil free base used as a starting material in the following examples was commercially available and in the form of N1 as described in WO 2021/129589 A1. Acesulfame used as starting material in the following examples was obtained by stirring an ethyl acetate suspension of acesulfame potassium and a stoichiometric amount of 85 % phosphoric acid for about 3 hours, filtering the organic layer and concentrating the solution to dryness.
PXRD Analysis:
[0076] PXRD diffractograms were recorded on a Broker D8 Discover powder X-ray diffractometer (Broker AXS LLC, Karlsruhe, Germany). The generator was a Incoatec Microfocus Source (IpS) Cu tube (A = 1 .54060 A) with a voltage of 50 kV and current of 1 .00 mA, using a divergence slit of 0.1 mm and collimator of 2.0 mm. For each sample, two frames were collected using a still scan with a PILATUS3 R 100K-A detector at the distance of 294.2 mm from the sample. Raw data were evaluated using the program DIFFRAC. EVA (Broker AXS LLC, Karlsruhe, Germany).
Example 1 : Preparation of belumosudil L-malate Form APO-I
[0077] To a suspension of belumosudil free base (100 mg) in a mixture of isopropanol (2.7 mL) and water (0.3 mL) at 60 °C was added solid L-malic acid (52 mg), and the resulting suspension was stirred at that temperature for one hour. The suspension was allowed to cool and stirring was continued at room temperature for approximately 16 hours, after which the solids were collected by filtration, washed with acetone (2 x 1 mL), and dried at room temperature in vacuo to afford belumosudil L-malate Form APO-I as a yellow solid (129 mg). The PXRD of the sample is shown in Figure 1 .
[0078] 1H NMR (500 MHz, DMSO-d6): 13.09 (br s, 1 H), 12.42 (br s, 2H), 9.97 (s, 1 H), 8.60 (d, J = 8.2 Hz, 1 H), 8.32 (s, 1 H), 8.16 (s, 1 H), 8.06 (br s, 1 H), 8.04 (d, J = 7.8 Hz, 1 H), 7.95 (d, J = 7.9 Hz, 1 H), 7.83-7.90 (m, 3H), 7.65 (d, J = 8.7 Hz, overlapping another signal, 2H), 7.42 (t, J = 7.9 Hz, 1 H), 7.08 ( br d, J = 8.2 Hz, 1 H), 4.52 (s, 2H), 4.26 (m, 1 H), 3.99 (m, 1 H), 2.62 (dd, J = 15.7, 4.8 Hz, 1 H), 2.44 (dd, J = 15.7, 7.8 Hz, 1 H), 1.12 (d, J = 6.6 Hz, 6H).
Example 2: Preparation of belumosudil acesulfamate Form APO-I
[0079] To a suspension of belumosudil free base (100 mg) in a mixture of isopropanol (2.7 mL) and water (0.3 mL) at 60 °C was added solid acesulfame (52 mg), and the resulting suspension was stirred at that temperature for one hour. The suspension was allowed to cool and stirring was continued at room temperature for approximately 16 hours, after which the solids were collected by filtration, washed with acetone (2 x 1 mL), and dried at room temperature in vacuo to afford belumosudil acesulfamate Form APO-I as a yellow solid (140 mg). The PXRD of the sample is shown in Figure 2.
[0080] 1H NMR (500 MHz, DMSO-d6): 13.22 (br s, 1 H), 11.00 (br s, 1 H), 8.70 (d, J = 8.3 Hz, 1 H), 8.22 (s, 1 H), 8.20 (d, J = 0.4 Hz, 1 H), 8.04 (t, J = 7.3 Hz, 1 H), 7.99 (d, J = 8.2 Hz, 1 H), 7.94 (d, J = 8.0 Hz, 1 H), 7.90 (br s, overlapping another signal, 2H), 7.79 (dd, J = 8.9, 1 .8 Hz, overlapping another signal, 2H), 7.70 (d, J = 8.9 Hz, 1 H), 7.52 (t, J = 7.9 Hz, 1 H), 7.22 ( br d, J = 7.2 Hz, 1 H), 5.56 (s, 1 H), 4.54 (s, 2H), 3.96 (m, 1 H), 2.01 (d, J = 0.7 Hz, 3H), 1 .09 (d, J = 6.6 Hz, 6H).
Example 3: Preparation of belumosudil fumarate Form APO-I
[0081 ] To a suspension of belumosudil free base (100 mg) in a mixture of isopropanol (2.7 mL) and water (0.3 mL) at 60 °C was added solid fumaric acid (51 mg), and the resulting suspension was stirred at that temperature for one hour. The suspension was allowed to cool and stirring was continued at room temperature for approximately 16 hours, after which the solids were collected by filtration, washed with acetone (2 x 1 mL), and dried at room temperature in vacuo to afford belumosudil fumarate Form APO-I as a yellow solid (119 mg). The PXRD of the sample is shown in Figure 3.
[0082] 1 H NMR (500 MHz, DMSO-d6): 13.14 (s, 3H), 9.97 (s, 1 H), 8.60 (d, J = 8.3 Hz,
1 H), 8.32 (s, 1 H), 8.16 (s, 1 H), 8.06 (br s, 1 H), 8.05 (d, J = 7.8 Hz, 1 H), 7.95 (d, J = 8.0 Hz, 1 H), 7.83-7.90 (m, 3H), 7.65 (d, J = 9.0 Hz, overlapping another signal, 2H), 7.42 (t, J = 7.9 Hz, 1 H), 7.08 ( br d, J = 8.0 Hz, 1 H), 6.64 (s, 2H), 4.53 (s, 2H), 3.99 (m, 1 H), 1 .11 (d, J = 6.6 Hz, 6H).
Example 4: Preparation of belumosudil maleate Form APO-I
[0083] To a suspension of belumosudil free base (100 mg) in a mixture of isopropanol (2.7 mL) and water (0.3 mL) at 60 °C was added solid maleic acid (59 mg), and the resulting suspension was stirred at that temperature for one hour. The suspension was allowed to cool and stirring was continued at room temperature for approximately 16 hours, after which the solids were collected by filtration, washed with acetone (2 x 1 mL), and dried at room temperature in vacuo to afford belumosudil maleate Form APO-I as a yellow solid (118 mg). The PXRD of the sample is shown in Figure 4.
[0084] 1 H NMR (500 MHz, DMSO-d6): 13.14 (s, 2H), 10.22 (s, 1 H), 8.62 (d, J = 8.3 Hz,
1 H), 8.30 (s, 1 H), 8.18 (s, 1 H), 8.02 (br s, 1 H), 8.00 (d, J = 7.9 Hz, 1 H), 7.88-7.96 (m, 3H), 7.83 (d, J = 8.9 Hz, 1 H), 7.66 (d, J = 8.6 Hz, overlapping another signal, 2H), 7.45 (t, J = 7.9 Hz, 1 H), 7.12 ( br d, J = 8.0 Hz, 1 H), 6.24 (s, 2H), 4.53 (s, 2H), 3.99 (m, 1 H), 1.11 (d, J = 6.6 Hz, 6H).
Example 5: Preparation of belumosudil isethionate Form APO-I
[0085] To a suspension of belumosudil free base (100 mg) in a mixture of isopropanol (3 mL) and water (1 mL) was added 2-hydroxyethanesulfonic acid (50 pL), and the resulting suspension was stirred at room temperature for approximately 16 hours, after which the solids were collected by filtration, washed with acetone (1 mL), and dried at room temperature in vacuo to afford belumosudil isethionate Form APO-I as a yellow solid (119 mg). The PXRD diffractogram of the sample is shown in Figure 5.
[0086] 1 H NMR (500 MHz, DMSO-d6): 13.27 (br s, 1 H), 11 .38 (br s, 1 H), 8.74 (d, J =
8.2 Hz, 1 H), 8.22 (s, 1 H), 8.19 (s, 1 H), 8.10 (t, J =7.2 Hz, 1 H), 8.05 (d, J = 7.9 Hz, 1 H), 7.95 (d, J = 7.9 Hz, 1 H), 7.86 (br s overlapping another signal, 3H), 7.77 (d, J = 8.9 Hz, 1 H), 7.72 (d, J = 8.9 Hz, 1 H), 7.56 (t, J = 7.9 Hz, 1 H), 7.27 ( br d, J = 7.8 Hz, 1 H), 4.55 (s, 2H), 3.96 (m, 1 H), 3.63 (t, J = 6.8 Hz, 2H), 2.62 (t, J = 6.8 Hz, 2H), 1.09 (d, J = 6.6 Hz, 6H).
Example 6: Preparation of belumosudil malonate Form APO-I
[0087] To a suspension of belumosudil free base (100 mg) in a mixture of isopropanol (3 mL) and water (1 mL) was added solid malonic acid (54 mg), and the resulting suspension was stirred at room temperature for approximately 16 hours, after which the solids were collected by filtration, washed with acetone (1 mL), and dried at room temperature in vacuo to afford belumosudil malonate Form APO-I as a yellow solid (101 mg). The PXRD diffractogram of the sample is shown in Figure 6.
[0088] 1H NMR (500 MHz, DMSO-d6): 13.09 (br s, 1 H), 12.71 (br s, 2H), 9.98 (s, 1 H), 8.60 (d, J = 8.2 Hz, 1 H), 8.32 (s, 1 H), 8.16 (s, 1 H), 8.06 (br s, 1 H), 8.03 (d, J = 7.7 Hz, 1 H), 7.94 (d, J = 7.9 Hz, 1 H), 7.83-7.90 (m, 3H), 7.65 (d, J = 8.6 Hz, overlapping another signal, 2H), 7.42 (t, J = 7.9 Hz, 1 H), 7.09 ( br d, J = 8.3 Hz, 1 H), 4.52 (s, 2H), 3.99 (m, 1 H), 3.24 (s, 2H), 1 .12 (d, J = 6.5 Hz, 6H).
Example 7: Preparation of belumosudil edisylate Form APO-I
[0089] To a suspension of belumosudil free base (100 mg) in a mixture of isopropanol (3 mL) and water (1 mL) was added solid 1 ,2-ethanedisulfonic acid dihydrate (25 mg),
and the resulting suspension was stirred at room temperature for approximately 16 hours, after which the solids were collected by filtration, washed with acetone (1 mL), and dried at room temperature in vacuo to afford belumosudil edisylate Form APO-I as a yellow solid (98 mg). The PXRD diffractogram of the sample is shown in Figure 7.
[0090] 1 H NMR (500 MHz, DMSO-d6): 13.24 (br s, 1 H), 11 .24 (br s, 1 H), 8.72 (d, J =
7.7 Hz, 1 H), 8.21 (s, 1 H), 8.07 (br m, 1 H), 8.03 (br m, 1 H), 7.95 (d, J = 8.0 Hz, 1 H), 7.89 (br s, overlapping another signal, 2H), 7.82 (br m, 1 H), 7.79 (d, J = 9.0 Hz, 1 H), 7.71 (d, J = 8.9 Hz, 1 H), 7.54 (t, J = 7.6 Hz, 1 H), 7.24 ( br d, J = 7.1 Hz, 1 H), 4.54 (s, 2H), 3.96 (m, 1 H), 2.64 (s, 2H), 1.10 (d, J = 6.5 Hz, 6H).
Example 8: Preparation of belumosudil citrate Form APO-I
[0091 ] To a suspension of belumosudil free base (100 mg) in acetone (3 mL) was added solid citric acid (42 mg), and the resulting suspension was stirred at room temperature for approximately 16 hours, after which the solids were collected by filtration, washed with acetone (2 x 1 mL), and dried at room temperature in vacuo to afford belumosudil citrate Form APO-I as a yellow solid (120 mg). The PXRD diffractogram of the sample is shown in Figure 8.
[0092] 1H NMR (500 MHz, DMSO-de): 13.09 (br s, 1 H), 12.33 (br s, 2H), 9.99 (s, 1 H), 8.60 (d, J = 8.3 Hz, 1 H), 8.32 (s, 1 H), 8.16 (s, 1 H), 8.06 (s, 1 H), 8.03 (d, J = 7.8 Hz, 1 H), 7.95 (d, J = 8.0 Hz, 1 H), 7.83-7.90 (m, 3H), 7.65 (d, J = 8.7 Hz, overlapping another signal, 2H), 7.42 (t, J = 7.9 Hz, 1 H), 7.09 ( br d, J = 7.8 Hz, 1 H), 5.21 (br s, 1 H), 4.52 (s, 2H), 3.99 (m, 1 H), 2.76 (d, J = 15.4 Hz, 2H), 2.66 (d, J = 15.4 Hz, 2H), 1 .12 (d, J = 6.6 Hz, 6H).
[0093] To a suspension of belumosudil free base (100 mg) in a mixture of acetone (3 mL) and water (1 mL) was added solid citric acid (86 mg), with complete dissolution of all solids being observed. After 12 days at room temperature, a brown, pasty and unstirrable precipitate had formed. The supernatant was decanted and acetone (3 mL) was added, converting the pasty precipitate into a free-flowing powder. The solids were collected by filtration, washed with acetone (2 x 1 mL), and dried at room temperature in vacuo to
afford belumosudil citrate Form APO-II as a yellow solid (136 mg). The PXRD diffractogram of the sample is shown in Figure 9.
Example 10: Preparation of belumosudil L-tartrate Form APO-I
[0094] To a belumosudil free base (100 mg) suspension in methanol (4 mL) was added solid L-tartaric acid (33 mg), and the resulting suspension was stirred at room temperature for approximately 4 hours, after which the solids were collected by filtration, washed with methanol (0.5 mL), and dried at room temperature in vacuo to afford belumosudil L-tartrate Form APO-I as a yellow solid (70 mg). The PXRD diffractogram of the sample is shown in Figure 10. [0095] 1H NMR (500 MHz, DMSO-d6): 12.87 (br s, 3H), 9.97 (s, 1 H), 8.60 (d, J = 8.3
Hz, 1 H), 8.32 (d, J = 1 .2 Hz, 1 H), 8.16 (s, 1 H), 8.06 (br s, 1 H), 8.04 (d, J = 7.8 Hz, 1 H), 7.94 (d, J = 8.0 Hz, 1 H), 7.86-7.90 (m, 2H), 7.85 (dd, J = 1 .8, 8.8 Hz, 1 H), 7.65 (d, J = 8.8 Hz, overlapping another signal, 2H), 7.42 (t, J = 7.9 Hz, 1 H), 7.09 (dd, J = 2.2, 8.1 Hz, 1 H), 5.11 (br s, 2H), 4.53 (s, 2H), 4.32 (s, 2H), 3.99 (m, 1 H), 1 .12 (d, J = 6.6 Hz, 6H).
Claims
What is claimed is:
1 . An L-malate salt of belumosudil.
2. The L-malate salt of belumosudil of claim 1 , wherein the molar ratio of belumosudil to L-malic acid is approximately 1 :1.
3. The L-malate salt of claim 2, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 29 (± 0.2°), at 6.4°, 7.6°, and 16.2°.
4. The L-malate salt of claim 3, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 26 (± 0.2°), selected from the group consisting of: 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °.
5. The L-malate salt of claim 3, further comprising peaks in the PXRD diffractogram, expressed in degrees 26 (± 0.2°), at 10.5°, 12.4°, 12.9°, 15.2°, 19.7°, and 21.1 °.
6. The L-malate salt of any one of claims 1 to 5, providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 29) as those shown in Figure 1 .
7. An acesulfamate salt of belumosudil.
8. The acesulfamate salt of belumosudil of claim 7, wherein the molar ratio of belumosudil to acesulfame is approximately 1 :1.
9. The acesulfamate salt of claim 8, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 29 (± 0.2°), at 4.8°, 6.5°, and 25.7°.
10. The acesulfamate salt of claim 9, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 29 (± 0.2°), selected from the group consisting of: 10.3°, 11.5°, 14.6°, 16.2°, 19.6°, and 20.7°.
11. The acesulfamate salt of claim 9, further comprising peaks in the PXRD diffractogram, expressed in degrees 29 (± 0.2°), at 10.3°, 11 .5°, 14.6°, 16.2°, 19.6°, and 20.7°.
12. The acesulfamate salt of any one of claims 7 to 11 , providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 2.
13. A fumarate salt of belumosudil.
14. The fumarate salt of belumosudil of claim 13, wherein the molar ratio of belumosudil to fumaric acid is approximately 1 :1.
15. The fumarate salt of claim 14, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 7.2°, 7.9°, and 21.1 °.
16. The fumarate salt of claim 15, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 12.7°, 13.6°, 18.7°, 20.1 °, 21.7°, and 23.8°.
17. The fumarate salt of claim 15, further comprising peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), at 12.7°, 13.6°, 18.7°, 20.1 °, 21 .7°, and 23.8°.
18. The fumarate salt of any one of claims 13 to 17, providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 3.
19. A maleate salt of belumosudil.
20. The maleate salt of belumosudil of claim 19, wherein the molar ratio of belumosudil to maleic acid is approximately 1 :1.
21. The maleate salt of claim 20, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 5.3°, 6.9°, and 10.8°.
22. The maleate salt of claim 21 , further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °.
23. The maleate salt of claim 21 , further comprising peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), at 12.2°, 15.0°, 17.3°, 18.3°, 22.7°, and 24.1 °.
The maleate salt of any one of claims 19 to 23, providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 4. An isethionate salt of belumosudil. The isethionate salt of belumosudil of claim 25, wherein the molar ratio of belumosudil to 2-hydroxyethanesulfonic acid acid is approximately 1 :1. The isethionate salt of claim 26, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.4°, 10.1 °, and 12.7°. The isethionate salt of claim 27, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°. The isethionate salt of claim 27, further comprising peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), at 7.8°, 15.7°, 19.2°, 20.3°, and 25.7°. The isethionate salt of any one of claims 25 to 29, providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 5. A malonate salt of belumosudil. The malonate salt of belumosudil of claim 31 , wherein the molar ratio of belumosudil to malonic acid is approximately 1 :1. The malonate salt of claim 32, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.3°, 9.8°, and 12.6°. The malonate salt of claim 33, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°.
35. The malonate salt of claim 33, further comprising peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), at 8.1 °, 15.2°, 16.3°, 19.0°, and 21.0°.
36. The malonate salt of any one of claims 31 to 35, providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 6.
37. An edisylate salt of belumosudil.
38. The edisylate salt of belumosudil of claim 49, wherein the molar ratio of belumosudil to 1 ,2-ethanedisulfonic acid is approximately 2:1 .
39. The edisylate salt of claim 38, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.7°, 7.7°, and 9.7°.
40. The edisylate salt of claim 39, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°.
41 . The edisylate salt of claim 39, further comprising peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), at 5.8°, 8.4°, 12.4°, 13.9°, 15.1 °, and 20.3°.
42. The edisylate salt of any one of claims 37 to 41 , providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 7.
43. A citrate salt of belumosudil.
44. The citrate salt of belumosudil of claim 43, wherein the molar ratio of belumosudil to citric acid is approximately 1 :1.
45. The citrate salt of claim 44, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.7°, 10.3°, and 11 .7°.
46. The citrate salt of claim 45, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°.
The citrate salt of claim 45, further comprising peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), at 7.3°, 12.5°, 14.6°, 16.4°, 19.1 °, and 19.8°. The citrate salt of any one of claims 43 to 47, providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 8. The citrate salt of claim 44, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 5.6°, 6.6°, and 17.7°. The citrate salt of claim 49, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 7.1 °, 11.2°, 12.6°, 15.4°, 15.9°, and 16.8°. The citrate salt of claim 49, further comprising peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), at 7.1 °, 11 .2°, 12.6°, 15.4°, 15.9°, and 16.8°. The citrate salt of any one of claims 49 to 51 , providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 9. An L-tartrate salt of belumosudil. The L-tartrate salt of belumosudil of claim 53, wherein the molar ratio of belumosudil to L-tartaric acid is approximately 1 :1. The L-tartrate salt of claim 54, characterized by a PXRD diffractogram comprising peaks, expressed in degrees 20 (± 0.2°), at 6.5°, 7.6°, and 16.3°. The L-tartrate salt of claim 55, further comprising at least three peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), selected from the group consisting of: 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°. The L-tartrate salt of claim 55, further comprising peaks in the PXRD diffractogram, expressed in degrees 20 (± 0.2°), at 10.6°, 12.5°, 15.3°, 18.4°, 19.5°, and 22.5°.
The L-tartrate salt of any one of claims 53 to 57, providing a PXRD diffractogram comprising peaks in substantially the same positions (± 0.2° 20) as those shown in Figure 10. A pharmaceutical composition comprising the salt of belumosudil according to any one of claims 1 to 58, and one or more pharmaceutically acceptable excipients. The pharmaceutical composition of claim 59, wherein the pharmaceutical composition is a tablet. The use of the salt of belumosudil according to any one of claims 1 to 60, or the pharmaceutical composition of claim 59 or 60, in the treatment of chronic graft- versus-host disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263357053P | 2022-06-30 | 2022-06-30 | |
US63/357,053 | 2022-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024000060A1 true WO2024000060A1 (en) | 2024-01-04 |
Family
ID=89383606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2023/050852 WO2024000060A1 (en) | 2022-06-30 | 2023-06-20 | Salts of belumosudil, crystalline forms and pharmaceutical compositions thereof and their use in the treatment of chronic graft-versus-host disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024000060A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006105081A2 (en) * | 2005-03-25 | 2006-10-05 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
WO2022020850A1 (en) * | 2020-07-22 | 2022-01-27 | Teva Pharmaceuticals International Gmbh | Solid state forms of belumosudil and belumosudil salts |
-
2023
- 2023-06-20 WO PCT/CA2023/050852 patent/WO2024000060A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006105081A2 (en) * | 2005-03-25 | 2006-10-05 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
WO2022020850A1 (en) * | 2020-07-22 | 2022-01-27 | Teva Pharmaceuticals International Gmbh | Solid state forms of belumosudil and belumosudil salts |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10525059B2 (en) | Pharmaceutical compositions comprising Afatinib | |
US11345706B2 (en) | Crystalline forms of Acalabrutinib | |
WO2023087101A1 (en) | Salts of ruxolitinib and crystalline forms thereof | |
US10662178B2 (en) | Crystalline form of Olaparib | |
US11236066B2 (en) | Crystalline forms of niraparib tosylate | |
EP3860606A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
WO2024000060A1 (en) | Salts of belumosudil, crystalline forms and pharmaceutical compositions thereof and their use in the treatment of chronic graft-versus-host disease | |
US11072620B2 (en) | Crystalline forms of Ponatinib hydrochloride | |
US11814356B1 (en) | Salt of cabozantinib | |
US20200317616A1 (en) | Crystalline Form of Betrixaban Maleate | |
US10961235B2 (en) | Crystalline form of masitinib | |
US20240116884A1 (en) | Salts of Viloxazine | |
US10611772B2 (en) | Crystalline form of Ribociclib succinate | |
US11667656B2 (en) | Crystalline forms of Tenofovir alafenamide | |
US20210292272A1 (en) | Salts of Zuclomiphene | |
US10632107B2 (en) | Crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
US20230093124A1 (en) | Salts of Nintedanib and Crystalline Forms Thereof | |
CA3135464A1 (en) | Novel salt of cabozantinib | |
RU2801812C2 (en) | Crystalline forms and methods for obtaining lenvatinib besylate | |
JP2019073445A (en) | Pharmaceutical composition containing aprepitant as active ingredient | |
CA3107017A1 (en) | Crystalline forms of tenofovir alafenamide | |
WO2023102645A1 (en) | Novel crystalline forms of apalutamide | |
CA3151879A1 (en) | Tenofovir alafenamide acesulfamate salt | |
JP2001072593A (en) | New pharmaceutical preparation of quinoline derivative and its production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23829319 Country of ref document: EP Kind code of ref document: A1 |